Q-omics provides the consensus-scored TM4SF18 profile across patient tissues and cancer cell-line models. TM4SF18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TM4SF18 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, TM4SF18 RNA expression shows 18,731 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where TM4SF18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM4SF18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM4SF18 survival associations across molecular data types. TM4SF18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM4SF18 RNA expression–survival associations across cancer types. High TM4SF18 expression shows unfavorable associations in STAD, MESO, UVM and SCLC, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TM4SF18 RNA expression.
This table summarizes TM4SF18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TM4SF18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM4SF18 shows lower tumor expression in KICH, LUSC and UCEC and higher tumor expression in KIRC, HNSC and LIHC. The KICH box plot shows higher TM4SF18 RNA expression in normal versus tumor tissue (log2 FC = −2.818, t-test p < 0.001).
This table shows molecular features associated with TM4SF18 in patient tissues and cancer cell lines. In patient samples, TM4SF18 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TM4SF18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
